25-Hydroxyvitamin D, IL-31, and IL-33 in Children with Allergic Disease of the Airways
Table 1
Demographic, clinical, and atopic characteristic of the subjects.
Control (HC)
Allergic rhinitis (AR)
Allergic asthma rhinitis (AAR)
Overall value
Age, (years) range
10.6 (±2.2) 8–12
10.3 (±2.1) 8–11
10.7 (±2.5) 9–13
ns
Sex, (male/female)
28 (17/11)
11 (8/3)
35 (22/13)
ns
Body mass index, (kg/m2) range
25.1 (±10.3) 17.8–32.3
18.6 (±4.8) 14.8–19.7
19.6 (±3.0) 17.1–21.3
ns
FEV1 (% predicted)
110.0 (±9.0)
107.7 (±16.7)
93.5 (±12.6)
<0.0001
FVC (% predicted)
95.5 (±19)
106 (±118)
92.9 (±12.1)
<0.0001
PEF (% predicted)
80.6 (±14.6)
79.7 (±18.6)
60.1 (±15.7)
<0.0001
SPT, any positive, (%)
0
100
100
<0.0001
Total IgE (IU/mL), (geometric mean) log tot IgE
39.7 1.60 (±0.21)
293.2 2.47 (±0.47)
320.5 2.51 (±0.41)
<0.0001 <0.0001
Total allergen sIgE score
0
6.0 (±3.3)
6.7 (±4.7)
<0.0001
Rast to dust mites
0
2.4 (±2.0)
2.1 (±2.0)
<0.0001
Exacerbations (last year)
0
NA
2.1 (±1.5)
<0.0001
Disease duration (yrs)
0
4.2 (±2.0)
5.6 (±2.5)
<0.0001
Data are presented as mean ± standard deviation unless otherwise stated. FEV1 = forced expiratory volume in 1 s; FVC = forced vital capacity; PEF = peak expiratory flow; SPT = skin prick test. Statistical analysis for multiple comparisons was calculated by Kruskal-Wallis test.
